Effect of an endothelin-receptor antagonist on ischemic acute renal failure. 1994

L Chan, and A Chittinandana, and J I Shapiro, and P F Shanley, and R W Schrier
Department of Medicine, University of Colorado School of Medicine, Denver 80262.

In the isolated perfused rat kidney, endothelin (ET) added to the perfusate at concentrations ranging from 50 to 500 pmol/l resulted in a dose-dependent reduction in renal perfusate flow (RPF) and inulin clearance (CIn). The decrease in RPF (17 +/- 3 vs. 34 +/- 3 ml.min-1 x g-1; P < 0.01 compared with control) and CIn (89 +/- 13 vs. 317 +/- 19 microliters.min-1 x g-1; P < 0.01 compared with control) by ET (500 pmol/l) was prevented by the ET antagonist BQ-123 (10 microM), with full recovery of RPF [36 +/- 2 vs. 34 +/- 3 ml.min-1 x g-1; not significant (NS) compared with control] and CIn (299 +/- 51 vs. 317 +/- 19 microliters.min-1 x g-1; NS compared with control). In the absence of ET, perfusion of the kidney with a similar concentration of BQ-123 (10 microM) did not induce any changes in RPF (36 +/- 5 vs. 34 +/- 3 ml.min-1 x g-1; NS compared with control) or CIn (320 +/- 14 vs. 317 +/- 19 microliters.min-1 x g-1; NS compared with control). After 60 min of arterial clamping, BQ-123 (10 microM) given before the onset of ischemia and during reflow improved CIn (88 +/- 4 vs. 19 +/- 3 microliters.min-1 x g-1; n = 6, P < 0.01) and net tubular sodium reabsorption (TNa) compared with no treatment. On the other hand, the same dose (10 microM) of BQ-123 given only during the reperfusion period was not effective in preventing the decreases in either CIn or TNa.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D007444 Inulin A starch found in the tubers and roots of many plants. Since it is hydrolyzable to FRUCTOSE, it is classified as a fructosan. It has been used in physiologic investigation for determination of the rate of glomerular function.
D007511 Ischemia A hypoperfusion of the BLOOD through an organ or tissue caused by a PATHOLOGIC CONSTRICTION or obstruction of its BLOOD VESSELS, or an absence of BLOOD CIRCULATION. Ischemias
D007684 Kidney Tubules Long convoluted tubules in the nephrons. They collect filtrate from blood passing through the KIDNEY GLOMERULUS and process this filtrate into URINE. Each renal tubule consists of a BOWMAN CAPSULE; PROXIMAL KIDNEY TUBULE; LOOP OF HENLE; DISTAL KIDNEY TUBULE; and KIDNEY COLLECTING DUCT leading to the central cavity of the kidney (KIDNEY PELVIS) that connects to the URETER. Kidney Tubule,Tubule, Kidney,Tubules, Kidney
D008297 Male Males
D010456 Peptides, Cyclic Peptides whose amino acid residues are linked together forming a circular chain. Some of them are ANTI-INFECTIVE AGENTS; some are biosynthesized non-ribosomally (PEPTIDE BIOSYNTHESIS, NON-RIBOSOMAL). Circular Peptide,Cyclic Peptide,Cyclic Peptides,Cyclopeptide,Orbitide,Circular Peptides,Cyclopeptides,Orbitides,Peptide, Circular,Peptide, Cyclic,Peptides, Circular
D010477 Perfusion Treatment process involving the injection of fluid into an organ or tissue. Perfusions
D012079 Renal Circulation The circulation of the BLOOD through the vessels of the KIDNEY. Kidney Circulation,Renal Blood Flow,Circulation, Kidney,Circulation, Renal,Blood Flow, Renal,Flow, Renal Blood
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D000042 Absorption The physical or physiological processes by which substances, tissue, cells, etc. take up or take in other substances or energy.
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

L Chan, and A Chittinandana, and J I Shapiro, and P F Shanley, and R W Schrier
October 1992, European journal of pharmacology,
L Chan, and A Chittinandana, and J I Shapiro, and P F Shanley, and R W Schrier
April 2001, Journal of cardiovascular pharmacology,
L Chan, and A Chittinandana, and J I Shapiro, and P F Shanley, and R W Schrier
July 1997, Current opinion in nephrology and hypertension,
L Chan, and A Chittinandana, and J I Shapiro, and P F Shanley, and R W Schrier
January 1994, Life sciences,
L Chan, and A Chittinandana, and J I Shapiro, and P F Shanley, and R W Schrier
January 2003, Acta pharmacologica Sinica,
L Chan, and A Chittinandana, and J I Shapiro, and P F Shanley, and R W Schrier
January 2000, Experimental nephrology,
L Chan, and A Chittinandana, and J I Shapiro, and P F Shanley, and R W Schrier
October 2002, Journal of cardiovascular pharmacology,
L Chan, and A Chittinandana, and J I Shapiro, and P F Shanley, and R W Schrier
April 2001, Kidney international,
L Chan, and A Chittinandana, and J I Shapiro, and P F Shanley, and R W Schrier
August 1999, Zhonghua bing li xue za zhi = Chinese journal of pathology,
L Chan, and A Chittinandana, and J I Shapiro, and P F Shanley, and R W Schrier
January 1997, European journal of pharmacology,
Copied contents to your clipboard!